

Heat shock protein inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/H4618448AF9EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: H4618448AF9EN

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Heat Shock Protein (Hsp) Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Heat Shock Protein (Hsp) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Heat Shock Protein (Hsp) Inhibitor Understanding

Heat Shock Protein (Hsp) Inhibitor: Overview

Heat Shock Proteins (HSPs) are a family of proteins that are transcriptionally upregulated under cellular stress including exposure to heat/ UV/ cold/pH changes, tissue remodeling etc. The HSPs are also called as 'chaperone' proteins as they bind and assist in correct protein folding and also help in refolding improperly folded proteins.

Function - Heat shock protein 90 (HSP90) is an important member of the chaperone protein family and it is involved in stabilization, regulation, and maintenance of oncogenic client proteins with co-chaperones. Cochaperones regulate the ATPase activity of HSP90 and its interactions with oncogenic client proteins. Therefore, HSP90 and its co-chaperones have become important therapeutic targets for cancer treatment.

This has led to the development of several inhibitors of HSP90 and other HSPs that have shown promise both preclinically and clinically in the treatment of cancer.

Heat Shock Protein (Hsp) Inhibitor - An Hsp90 inhibitor is a substance that inhibits the activity of the Hsp90 heat shock protein. Since Hsp90 stabilizes a variety of proteins required for survival of cancer cells, these substances may have therapeutic benefit in the treatment of various types of malignancies. Furthermore, a number of Hsp90 inhibitors are currently undergoing clinical trials for a variety of cancers. Hsp90 inhibitors include the natural products geldanamycin and radicicol as well as semisynthetic derivatives.

Heat Shock Protein (Hsp) Inhibitor Emerging Drugs Chapters

This segment of the Heat Shock Protein (Hsp) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Heat Shock Protein (Hsp) Inhibitor Emerging Drugs

Pimipib (TAS 116): Taiho Pharmaceutical

TAS-116, a compound discovered by Taiho Pharmaceutical, inhibits HSP90, thereby showing an anticancer effect by destabilizing and reducing proteins such as KIT, PDGFRA, HER2, and EGFR which are involved in the growth and survival of cancer. It is currently in phase 3 stage of clinical trials for the treatment of Gastrointestinal stromal tumours

RTA 901: Reata Pharmaceuticals

RTA 901 is a highly potent and selective, oral, small molecule C-terminal modulator of Hsp90. In preclinical rodent disease models, it was observed that RTA 901 administered orally once-daily rescued existing nerve function, restored thermal and mechanical sensitivity within four weeks, and improved nerve conductance velocity and mitochondrial function. These effects are dose-dependent, reversible, and HSP70-dependent. currently, it is in phase 1 of development stage for the treatment of

Diabetic neuropathies.

Further product details are provided in the report.....

Heat Shock Protein (Hsp) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Heat Shock Protein (Hsp) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Heat Shock Protein (Hsp) Inhibitor

There are approx. 15+ key companies which are developing the Heat Shock Protein (Hsp) Inhibitor. The companies which have their Heat Shock Protein (Hsp) Inhibitor drug candidates in the most advanced stage, i.e. phase III include, Taiho Pharmaceutical.

Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Heat Shock Protein (Hsp) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Heat Shock Protein (Hsp) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heat Shock Protein (Hsp) Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heat Shock Protein (Hsp) Inhibitor drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Heat Shock Protein (Hsp) Inhibitor R&D. The therapies under development are focused on novel approaches for Heat Shock Protein (Hsp) Inhibitor.

Heat Shock Protein (Hsp) Inhibitor Report Insights

Heat Shock Protein (Hsp) Inhibitor Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Heat Shock Protein (Hsp) Inhibitor Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Heat Shock Protein (Hsp) Inhibitor drugs?

How many Heat Shock Protein (Hsp) Inhibitor drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Heat Shock Protein (Hsp) Inhibitor?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Heat Shock Protein (Hsp) Inhibitor therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Heat Shock Protein (Hsp) Inhibitor and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Taiho Pharmaceutical

Reata Pharmaceuticals

Soligenix

Exelixis

Third Coast Therapeutics

Serenex

Chia Tai Tianqing Pharmaceutical Group

Wakamoto

Samus Therapeutics

Aldeyra Therapeutics

Joseah Biopharma

Novartis

Vernalis

Astex Pharmaceuticals

Minneamrita Therapeutics

RESprotect

Key Products

Pimitespib (TAS 116)

RTA 901

XL 888

3 crx 98

SNX 5422

TQB 3474

WP 1303

Zelavespib

ADX-1612

ADX-1615

MPT0B640

NVP BEP 800

Onalespib

Minnelide

Brivudine

Contents

Introduction

Executive Summary

Heat Shock Protein (Hsp) Inhibitor: Overview

- Structure
- Mechanism of Action

Pipeline Therapeutics

- Comparative Analysis

Therapeutic Assessment

- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type

Heat Shock Protein (Hsp) Inhibitor – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

- Heat Shock Protein (Hsp) Inhibitor companies' collaborations, Licensing, Acquisition -Deal Value Trends

Heat Shock Protein (Hsp) Inhibitor Collaboration Deals

- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

- Comparative Analysis

Pimitespib: Taiho Pharmaceutical

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

- Comparative Analysis

SNX 5422: Serenex

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

- Comparative Analysis

RTA 901: Reata Pharmaceuticals

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

- Comparative Analysis

NVP BEP 800: Vernalis

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

- Comparative Analysis

Heat Shock Protein (Hsp) Inhibitor Key Companies**Heat Shock Protein (Hsp) Inhibitor Key Products****Heat Shock Protein (Hsp) Inhibitor- Unmet Needs****Heat Shock Protein (Hsp) Inhibitor- Market Drivers and Barriers****Heat Shock Protein (Hsp) Inhibitor- Future Perspectives and Conclusion****Heat Shock Protein (Hsp) Inhibitor Analyst Views****Heat Shock Protein (Hsp) Inhibitor Key Companies****Appendix**

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Heat shock protein inhibitors
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Heat shock protein inhibitors
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Heat shock protein inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/H4618448AF9EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H4618448AF9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970